MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Achaogen Company Profile (NASDAQ:AKAO)

Consensus Ratings for Achaogen (NASDAQ:AKAO) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $12.67 (218.26% upside)

Analysts' Ratings History for Achaogen (NASDAQ:AKAO)
Show:
DateFirmActionRatingPrice TargetActions
6/14/2016WedbushUpgradeNeutral -> Outperform$7.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015Cantor FitzgeraldReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2015Credit Suisse Group AGDowngradeOutperform -> Underperform$22.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2014SunTrust Banks Inc.Initiated CoverageBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2014Canaccord GenuityInitiated CoverageBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/19/2014GabelliUpgradeHold -> Buy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for Achaogen (NASDAQ:AKAO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
3/15/2016Q414($0.58)($0.61)$5.33 million$4.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015($0.45)($0.48)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015($0.20)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015($0.26)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015($0.33)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.25)($0.47)$6.00 million$4.52 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.48)($1.00)$5.39 million$6.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Achaogen (NASDAQ:AKAO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.71)($0.52)($0.62)
Q2 20164($0.71)($0.52)($0.62)
Q3 20164($0.56)($0.39)($0.49)
Q4 20164($0.58)($0.29)($0.48)
Q1 20171($0.49)($0.49)($0.49)
Q2 20171($0.54)($0.54)($0.54)
Q3 20171($0.59)($0.59)($0.59)
Q4 20171($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)
Dividend History for Achaogen (NASDAQ:AKAO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Achaogen (NASDAQ:AKAO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/17/2016Ian FriedlandInsiderSell1,772$3.22$5,705.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Kenneth J HillanCEOSell3,572$3.22$11,501.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Achaogen (NASDAQ:AKAO)
DateHeadline
07/01/16 07:39 PMAchaogen Inc. (AKAO) Jumps 5.01% on July 01 - Equities.com
07/01/16 02:26 PMShares Headed Up in Session: Achaogen, Inc. (NASDAQ:AKAO) - Telanagana Press
06/30/16 02:27 PMAchaogen, Inc. (NASDAQ:AKAO) Company Rating and Target Watch - Telanagana Press
06/29/16 07:34 PMAchaogen Incorporated (NASDAQ:AKAO) Short Interest Increased By 44.43% - Engelwood Daily
06/29/16 07:34 PMWatching Stock Volatility for: Achaogen, Inc. (NASDAQ:AKAO) - Engelwood Daily
06/29/16 02:23 PMShare Update and Earnings Review for Achaogen, Inc. (NASDAQ:AKAO) - Press Telegraph
06/26/16 02:22 PMAchaogen, Inc. (AKAO) Broker Price Targets For The Coming Week - Fiscal Standard
06/26/16 07:22 AMStrong Sell Calls Recommendations For Achaogen, Inc. (NASDAQ:AKAO) At 0 - Investor Newswire
06/24/16 03:09 PMACHAOGEN INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Shee -
06/24/16 09:46 AMAchaogen Inc. (AKAO) Drops 5.19% on June 22 - Equities.com
06/24/16 07:10 AMAchaogen Announces New Employment Inducement Grants - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 24, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) ...
06/22/16 07:12 AMAchaogen Inc. (AKAO) Drops 5.53% on June 20 - Equities.com
06/21/16 02:23 PMAchaogen : Plazomicin Highlighted in Multiple Presentations at ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens
06/20/16 01:00 PMETF’s with exposure to Achaogen, Inc. : June 20, 2016 -
06/20/16 08:09 AMAchaogen's Plazomicin Highlighted in Multiple Presentations at ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) ...
06/20/16 07:30 AMAchaogen’s Plazomicin Highlighted in Multiple Presentations at ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., June 20, 2016-- Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant gram-negative infections, today announced ...
06/19/16 07:08 AMAchaogen, Inc. (AKAO) Analyst Price Targets For The Coming Week - Fiscal Standard
06/18/16 10:25 AM9 Analyst Stocks Under $10 With Massive Upside Calls -
06/17/16 02:24 PMSummary of Price Movements: Achaogen, Inc. (NASDAQ:AKAO) , AmpliPhi Biosciences Corporation (NYSEMKT:APHB) - Street Updates
06/16/16 03:06 PMACHAOGEN INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/16/16 02:25 PMAchaogen (AKAO) Shows Strength: Stock Moves 17.8% Higher - Nasdaq
06/16/16 07:15 AMAchaogen (AKAO) Shows Strength: Stock Moves 17.8% Higher -
06/15/16 07:29 PMDoes Achaogen Inc. (NASDAQ:AKAO) Have Enough Cash To Survive? - Scibility Media
06/15/16 07:29 PMAchaogen Inc. (AKAO) Jumps 17.76% on June 15 - Equities.com
06/15/16 02:27 PMAnalyst Best Overview on These Stocks: Achaogen, Inc. (NASDAQ:AKAO), Great Plains Energy Incorporated (NYSE ... - Beacon Chronicle
06/15/16 02:27 PMBiotech's Biggest Movers: Achaogen Inc (NASDAQ:AKAO) and Perrigo Company plc Ordinary Shares (NYSE:PRGO) - Market Exclusive
06/15/16 07:14 AMNotable Analyst Calls: GoPro (GPRO), Achaogen (AKAO), Navistar (NAV) - Wall Street Pit
06/15/16 07:14 AMAchaogen Inc. (AKAO) Jumps 8.44% on June 14 - Equities.com
06/15/16 05:11 AM[$$] Achaogen Stock Could Surge to $10 -
06/14/16 02:25 PMAchaogen Inc. (AKAO) Is Up Sharply Following Upgrade
06/14/16 09:05 AMAchaogen Shares Upgraded To Outperform By Wedbush Following Optimistic Survey - Wedbush's Heather Behanna upgraded Achaogen Inc (NASDAQ: AKAO) to Outperform, increasing the price objective from $7.00 to $10.00. After conducting a survey among physicians to analyze the gram-negative landscape and the "potential" for Achaogen's plazomicin, Behanna believes plazomicin had a "niche opportunity that can grow if Phase III data confirms its differentiated safety profile from the aminoglycoside class." Physicians were most interested in ...Full story available on Benzinga.com
06/14/16 05:44 AMAchaogen upgraded by Wedbush -
06/10/16 02:24 PMTrend Of Rating Given To Achaogen, Inc. (NASDAQ:AKAO) - Investor Newswire
06/09/16 07:49 AMAchaogen Announces Plazomicin Data Presentations at ASM Microbe 2016 Annual Meeting - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 09, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) ...
06/08/16 08:45 PMAchaogen Inc. (AKAO) is Trading Higher on Unusual Volume for June 07 - Equities.com
06/08/16 02:50 PMNew Broker Ratings For Achaogen, Inc. (AKAO) - FTSE News
06/08/16 10:53 AMAchaogen, Inc. (NASDAQ:AKAO) Went Up 8.33%: Delcath Systems, Inc. (NASDAQ:DCTH), Barrett Business Services ... - KC Register
06/07/16 08:00 PMAchaogen Inc. (AKAO) Jumps 8.33% on June 07 - Equities.com
06/06/16 01:16 PMCFO Moves: Achaogen Inc. -
06/06/16 01:16 PMCFO Moves: Achaogen Inc. -
06/06/16 11:59 AMAchaogen (AKAO) Stock: Weak On High Volume Today - TheStreet.com
06/05/16 07:43 PMAchaogen (AKAO) Shows Strength: Stock Moves 13% Higher - Yahoo News
06/05/16 10:15 AMTrade-Ideas: Achaogen (AKAO) Is Today's Strong On High Relative Volume Stock - TheStreet.com
06/04/16 10:53 AMAchaogen Inc. (AKAO) is Trading Higher on Unusual Volume for June 02 - Equities.com
06/03/16 08:27 PMAchaogen Inc. (AKAO) Jumps 8.86% on June 03 - Equities.com
06/03/16 03:04 PMACHAOGEN INC Files SEC form 8-K, Change in Directors or Principal Officers -
06/03/16 02:26 PMAchaogen (AKAO) Shows Strength: Stock Moves 13% Higher - Nasdaq
06/03/16 02:26 PMTop 2 Stocks To Buy: Achaogen, Inc. (NASDAQ:AKAO), Medtronic plc (NYSE:MDT) - Beacon Chronicle
06/03/16 02:26 PMHome Biotech Stocks Achaogen Inc. | $AKAO Stock | Shares Soar After Being Awarded... - TickerTV News (press release)
06/03/16 02:26 PMHealthcare Stock Picking: Achaogen Inc (NASDAQ:AKAO) - The Point Review
About Achaogen

Achaogen logoAchaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AKAO
  • CUSIP:
Key Metrics:
  • Previous Close: $3.98
  • 50 Day Moving Average: $3.63
  • 200 Day Moving Average: $3.88
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $73.26M
  • Current Quarter EPS Consensus Estimate: $-2.42 EPS
Additional Links:
Achaogen (NASDAQ:AKAO) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha